CDMO vs. APLT, ATXS, AVTE, ABUS, AVBP, CMPS, IGMS, LRMR, VERV, and ALT
Should you be buying Avid Bioservices stock or one of its competitors? The main competitors of Avid Bioservices include Applied Therapeutics (APLT), Astria Therapeutics (ATXS), Aerovate Therapeutics (AVTE), Arbutus Biopharma (ABUS), ArriVent BioPharma (AVBP), COMPASS Pathways (CMPS), IGM Biosciences (IGMS), Larimar Therapeutics (LRMR), Verve Therapeutics (VERV), and Altimmune (ALT). These companies are all part of the "pharmaceutical preparations" industry.
Avid Bioservices (NASDAQ:CDMO) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Applied Therapeutics has a net margin of 0.00% compared to Avid Bioservices' net margin of -13.10%. Applied Therapeutics' return on equity of 0.00% beat Avid Bioservices' return on equity.
Avid Bioservices received 296 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 66.49% of users gave Avid Bioservices an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
97.2% of Avid Bioservices shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 2.4% of Avid Bioservices shares are owned by insiders. Comparatively, 19.1% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Avid Bioservices has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.
Avid Bioservices currently has a consensus price target of $14.50, suggesting a potential upside of 67.24%. Applied Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 150.57%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Avid Bioservices.
Avid Bioservices has higher revenue and earnings than Applied Therapeutics. Avid Bioservices is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Applied Therapeutics had 4 more articles in the media than Avid Bioservices. MarketBeat recorded 9 mentions for Applied Therapeutics and 5 mentions for Avid Bioservices. Avid Bioservices' average media sentiment score of 0.65 beat Applied Therapeutics' score of 0.17 indicating that Avid Bioservices is being referred to more favorably in the media.
Summary
Applied Therapeutics beats Avid Bioservices on 11 of the 18 factors compared between the two stocks.
Get Avid Bioservices News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avid Bioservices Competitors List
Related Companies and Tools
